CA2074108A1 - Hydrogen peroxide disinfection solutions - Google Patents
Hydrogen peroxide disinfection solutionsInfo
- Publication number
- CA2074108A1 CA2074108A1 CA002074108A CA2074108A CA2074108A1 CA 2074108 A1 CA2074108 A1 CA 2074108A1 CA 002074108 A CA002074108 A CA 002074108A CA 2074108 A CA2074108 A CA 2074108A CA 2074108 A1 CA2074108 A1 CA 2074108A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- hydrogen peroxide
- surface active
- active agent
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
- A61L12/124—Hydrogen peroxide; Peroxy compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
Abstract
Improvement in Hydrogen Peroxide Disinfection Solutions Abstract of the Disclosure The efficacy of buffered H2O2 disinfecting formulations for contact lenses is improved by incorporating into such formulations a surface active agent.
Description
2Q7~
Improvement in Hvdrogen Peroxide Disinfection Solutions The present invention provides an improvement in hydrogen peroxide disinfection solutions. Specifically, the invention provides improvement in such disinfection solutions employed in the disinfection of contact lenses.
Disinfecting solutions for use with contact lenses are well known in the art and the use of such lenses involves a daily disinfecting treatment. Flexible, or soft, contact lenses are generally made from hydrophilic polymers and the hydroxy groups of these lenses attract and retain substantial amounts of water in the plastic which results in difficulties during cleaning and sterilization.
Furthermore, hydrophilic flexible contact lenses have a tendency to complex with and concentrate certain preservatives and disinfecting agents used in sterilizing conventional contact lenses. If these preservatives come into contact with the cornea they can cause severe irritation and burning.
Hydrogen peroxide systems, and particular a 3 % hydrogen peroxide solution, haveemerged as the disinfectant of choice for all types of daily and extended wear hydrogen lenses. The primary reason for its increasing popularity is its rapid kill of microbial contaminants and its non-residual character. After hydrogen peroxide disinfects lenses, it can be converted into innocuous by-products which are compatible with ocular physiology. See Krezanoski et al., "Journal of the American Optometric Association", Vol. 59, Number 3, pages 193-197 (1988).
A great deal of patent literature is available concerning hydrogen peroxide contact lens disinfection systems. Reference is made in this respect to the following:
Gaglia, Jr., U.S. Patent No. 3,912,451;
LaRouzie et al., U.S. Patent No. 4,743,447;
Davies et al., International Patent Publication WO 86/05695;
Andermann et al., U.S. Patent No. 4,880,601;
Giefer, U.S. Patent No. 4,585,488.
Improvement in Hvdrogen Peroxide Disinfection Solutions The present invention provides an improvement in hydrogen peroxide disinfection solutions. Specifically, the invention provides improvement in such disinfection solutions employed in the disinfection of contact lenses.
Disinfecting solutions for use with contact lenses are well known in the art and the use of such lenses involves a daily disinfecting treatment. Flexible, or soft, contact lenses are generally made from hydrophilic polymers and the hydroxy groups of these lenses attract and retain substantial amounts of water in the plastic which results in difficulties during cleaning and sterilization.
Furthermore, hydrophilic flexible contact lenses have a tendency to complex with and concentrate certain preservatives and disinfecting agents used in sterilizing conventional contact lenses. If these preservatives come into contact with the cornea they can cause severe irritation and burning.
Hydrogen peroxide systems, and particular a 3 % hydrogen peroxide solution, haveemerged as the disinfectant of choice for all types of daily and extended wear hydrogen lenses. The primary reason for its increasing popularity is its rapid kill of microbial contaminants and its non-residual character. After hydrogen peroxide disinfects lenses, it can be converted into innocuous by-products which are compatible with ocular physiology. See Krezanoski et al., "Journal of the American Optometric Association", Vol. 59, Number 3, pages 193-197 (1988).
A great deal of patent literature is available concerning hydrogen peroxide contact lens disinfection systems. Reference is made in this respect to the following:
Gaglia, Jr., U.S. Patent No. 3,912,451;
LaRouzie et al., U.S. Patent No. 4,743,447;
Davies et al., International Patent Publication WO 86/05695;
Andermann et al., U.S. Patent No. 4,880,601;
Giefer, U.S. Patent No. 4,585,488.
2~741Q~
In general, the hydrogen peroxide systems involve a hydrogen peroxide-containingdisinfecting solution into which the contact lenses to be disinfected are placed and allowed to remain for a required period of time. Nascent oxygen is released providing a germicidal effect. Following the requisite time period a purposeful inactivation of the hydrogen peroxide is conducted, for example, with a platinum catalyst. Following inactivation, the contact lens may be reinserted into the eye.
The hydrogen peroxide disinfecting solutions may be of the buffered or unbuffered type.
As examples, AOSept(g) is a stabilized 3 % hydrogen peroxide solution made isotonic with sodium chloride and buffered to an approximate pH 6.9 with phosphates. On the other hand, LenSept(~) is a non-buffered 3 % hydrogen peroxide formulation.
The present invention is based upon the discovery that it is possible to improve the killing effectiveness and the rate of kill of both fungi and bacteria by modifying the buffered hydrogen peroxide disinfecting solution to incorporate therein an ocularly compatible surface active agent in a specified amount. Thus, the invention provides an improvement in a buffered hydrogen peroxide disinfecting solution which comprises incorporating into said solution from about 0.1 % to about 1.0 % by weight of the solution of an ocularly compatible surface active agent. Thus, the invention is directed to, in a buffered hydrogen peroxide formulation for disinfecting contact lenses, the improvement wherein said formulation contains from about 0.1 % to about 1.0 % by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation, and to improved buffered hydrogen peroxide formulations comprising from about 0.1 % to about 1.0 % by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation, and to the use of such formulations for the disinfection of contact lenses.
Gaglia, Jr., U.S. Patent No. 3,912,451 discloses buffered hydrogen peroxide solutions of the type to which the present invention can be applied and for which improvement can be achieved.
By addition of the surface active agent to the buffered hydrogen peroxide disinfecting solution it is possible to improve the killing effectiveness and the rate of kill of both fungi and bacteria.
2~741Q8 With most 3 % hydrogen peroxide formulations, there are some viable organisms remaining even after a 30 minute soaking time of the contact lens. However, with the improvement of this invention, it is possible to provide a formulation in which there are no viable organisms after a 30 minute soaking time. With the current peroxide formulations there is a "lag" time between the time when the organisms are placed in the peroxide and the time when actual killing occurs. With the addition of the surface active agent, this "lag" time is reduced significantly and the rate of kill is enhanced.
In the literature it has been indicated that hydrogen peroxide formulations are not effective for contact lenses without a full-strength soaking for a minimum of 55 minutes. With this invention, however, it is possible to reduce considerably the disinfection time and obtain more complete disinfection.
The hydrogen peroxide formulations to which the surface active agent is added are of the buffered type. In general, in formulating such solutions a 3 % by weight hydrogen peroxide solution is formulated to contain 0.85 % by weight soldium chloride. Upon the ultimate conversion of the H22 to water and oxygen by catalyst this will yield an approximately isotonic saline solution as the final product. With the sodium chloride there is added to the H2O2 solution the necessary buffer system to buffer the 0.85 % aqueous sodium chloride solution to the desired pH of about 6.9 to 7.1.
The buffer system may comprise a suitable combination of monobasic sodium phosphate and dibasic sodium phosphate. Other satisfactory buffer systems may be employed which give substantially equivalent results in buffering to a pH of 6.9 to 7.1. As examples there can be mentioned tartrate, succinate and glycine buffers or the MacIlvaine phosphate-citrate buffer as described in J. Biol. Chem., 183 (1921).
To the solution can also be added a hydrogen peroxide stabilizer such as sodium stannate or sodium nitrate. Such stabilizers are known in the art. In addition, as the stabilizer there can be employed diethylene triamine penta (methylenephosphonic acid) or a physiologically compatible salt thereof (see U.S. Patent No. 4,889,689).
As an example of the buffered type hydrogen peroxide formulation, there can be mentioned the commercially available AOSept~) forrnulation.
2~7~1~8 In the broadest sense the surface active agents which can be used are those which are ocularly compatible and which function in the buffered hydrogen peroxide formulations to improve the killing effectiveness of such formulations. Preferably the surface active agent is a nonionic surface active agent. As specific examples of the surface active agents the following may be mentioned:
Polyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactants which are more commonly known as "Tetronic(~)" type surfactants. These are also generally known by the generic name "poloxamine" and are commercially available from BASF-Wyandotte Corp.
Polyoxyethylene-polyoxypropylene nonionic surfactants sold under the trademark "Pluronic(~)" by BASF-Wyandotte Corp. These surfactants are generally known as "poloxamers" and typically have a molecular weight of between about 2,000 and about 5,000.
Polysorbates, such as "Tween(g)" surfactants (ICI Americas) including, for example poly-sorbate 20, 40, 60, 65, 80 and 85.
Tyloxapol, such as "Superinone(~)" detergent (Winthrop).
Miranol(g) amphoteric surfactants from Miranol Inc. such as "Miranol(~)" 2MCA which is lauryl sulfate salt of an amphoteric surfactant derived from coconut imidazoline.
Varonic(~ LI surfactants such as Varonic(~ LI-63 and LI-67 which are ethoxylatedglyceryl monococoates. These are commercially available from Sherex Chemical Company, Inc..
Varsulf anionic sulfosuccinates such as Varsulf SBFA-30 and Varsulf SBL-203. These are commercially available from Sherex Chemical Company, Inc..
The foregoing are merely illustrative and not exhaustive of the surface active agents which can be employed in the invention.
One skilled in the art will be able to readily determine whether a given surface active agent or mixture of such agents can be employed. First, it is necessary to determine that 20741~8 such aKent or mixture of agents is ocularly compatible. Tests for determining such compatibility are well known in the art~. Such agent or mixture must not cause irritation or damage to the eye of a contact lens wearer. Secondly, the agent or mixture must be one which improves the killing efficacy of the buffered H2O2 formulation. Standard challenge organisms are known against which the buffered H2O2 formulation alone and that formu-lation containing the surface active agent or mixture can be compared. It is not, of course, essential that the agent or mixture of agents improve the efficacy against every challenge organism, it being most important that the overall spectrum of activity be improved.
It is also to be noted that these surface active agents can be employed alone or in combination. Preferred is e.g. a mixture of a poloxamine type and a poloxamer type surface active agent. Also preferred is a mixture of a poloxamine type and a polysorbate type surface active agent.
The surface active agent is added to the hydrogen peroxide formulation in an amount from about 0.1 % to about 1.0 % by weight of the formulation, preferably from about 0.1 % to about 0.6 % by weight of the formulation and more preferred from about 0.1 to about 0.4 % by weight of the formulation.
Particularly suitable for use in the invention are the nonionic poloxamine and poloxamer type surfactants as disclosed in European Patent Application EP-A2-439,429. These materials offer the further advantage of providing conditioning properties for the contact lenses by rendering the contact lens surface more wettable so that proteins, lipids and other tear ~llm substituents do not adhere to and form deposits on the lens surface. Some relevant parts of EP-A2-439,429 are repeated hereinafter:
"The present invention relates to a conditioning solution for contact lenses which comprises an effective amount of a polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant having a hydrophile-lipophile balance of seven or below. These surfactants preferably have a molecular weight of between about 3,600 and about 9,000. Such surfactants are typically known generally as "Poloxamine", and sold under the trademark Tetronics(~) (BASF-Wyandotte Corp.).
Preferred are those solutions wherein said polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant has a polyoxyethylene concentration between about 10 % and about 20 % by weight.
20741~8 The solution may also have an effective amount of a polyoxyethylene-polyoxy-propylene nonionic surfactant having a hydrophile-lipophile balance of seven or below and a polyo~cyethylene concentration of less than about 20 % by weight. Such surfactants are generally known as "Poloxamers" and sold under the trademark Pluronics(~) (BASF-Wyandotte Corp.). They typically have a molecular weight of between about 2,000 and about 5,000.
.....
The polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant and the polyoxyethylene-polyoxypropylene nonionic surfactant are bothsurface active agents which have as low a hydrophile-lipophile balance (HLB) as will be tolerated in the formulations. The low HLB values in the surface active agent indicate a high affinity for hydrophobic (lipophilic) surfaces. These surfaces active agents strongly adhere to those hydrophobic regions of the contact lens and render them hydrophilic. This adherence forms a "barrier" to potential absorbance, and keeps them from the surface of the lens. Furthermore, this increase in hydrophilicity simultaneously decreases the thermodynamic driving force for protein and lipid absorption, thereby retarding tear film deposits.
As mentioned hereinbefore the poloxamine type surfactants are more commonly known as Tetronic(~) type surfactants. The Tetronic(~) type surfactant is a tetrafunctional block copolymer derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine, and is represented by the followingstructure:
H-(OCH2CH2)m3~(0cHcH2)n3 \ /(CH2lHO)n1-(cH2cH2o)m1-H
~ N-CH2-CH2-N
H-(OCH2CH2)m4~(0clHcH2)n4 \(CH2CHO)n2-(CH2CH20)m2-H
wherein nl to n4 and ml to m4 are numbers being a function of the desired molecular weight and the ratio of ethyleneoxy groups to propyleneoxy groups. The 7 ~ 41~8 preparation thereof can be found in U.S. Patent No. 2,979,528, which is incorporated herein by reference. For convenience purposes, these nonionic surfactants will be identified generally as Tetronic(~, with a numeral suffix to identify a particular grade of material as available from BASF-Wyandotte Corp.
It has been surprisingly discovered that only tetronics having a hydrophile-lipophile balance of seven or below are suitable for use in the conditioning solution of the present invention. Such tetronics typically have the molecular weight of betweenabout 3,600 and about 9,000 and include Tetronic 701; 702; 901; 1101; 1102; 1301;
1302; 1501; and 1502 from BASF-Wyandotte.
The poloxamer type surfactants comprise a series of closely related block polymers that may generally be classified as polyoxyethylene-polyoxypropylene condensatesterminating in hydroxyl groups. They are formed by the condensation of propyleneoxide onto a propylene glyconucleus followed by the condensation of ethylene oxide onto both ends of polyoxypropylene base. The polyoxyethyl hydrophilic groups on the ends of the molecule are controlling length to constitute anywhere from 10 % to 80 % by weight of the final molecule. The structure of the polyethylene-polyoxy-propylene nonionic surfactant is preferably as follows:
HO-(CH2CH20)X1 -(CH2CHO)y~(CH2CH20)x2~H
wherein xl, x2 and y are numbers being a function of the desired molecular weight and the ratio of ethyleneoxy groups to propyleneoxy groups. For convenience purposes, these nonionic surfactants will be referred to herein as Pluronic(~) generally, with a numerical suffix to identify a particular grade of material asavailable from BASF-Wyandotte Corp.
It has further been discovered that the polyoxyethylene-polyoxypropylene nonionic surfactant useful in the present invention must have a HLB of seven or below and a polyoxyethylene concentration of less than about 20 % by weight. Such preferred surfactants include Pluronic L61, L81, L101 and L121 from BASF-Wyandotte Corp.
These polyoxyethylene-polyoxypropylene nonionic surfactants have a molecular weight of between about 2,000 and about 5,000."
20~41~-~
Also particularly suitable for use is a mixture of a poloxamine, e.g. poloxamine 1302 (lbtronic(~)), and a polysorbate, e.g. polysorbate 80 (Tween(~ 80), in amounts of about 0.1 % by weight and about 0.4 % by weight respectively.
In order to exemplify the invention, compositions were compared for their relative dis-infection capacity in respect to certain challenge microorganisms. The organisms tested are the FDA challenge organisms for disinfection solutions. The time required to kill 50 %
of the colony forming units (CFU) in solution was designated as the D-value. The initial solution employed was a commercially available AOSept(~) solution which is a 3 %buffered hydrogen peroxide solution also containing a hydrogen peroxide stabilizer. The solution of the present invention for comparison is prepared by adding to the commercially available AOSept~ initial solution, a mixture of polyoxamine 1302 (Tetronic~)) and polysorbate 80 (Tween(~) 80) in amounts sufficient to constitute 0.1 %
and 0.4 % by weight respectively of the formulation. The results are shown in the table below:
D-VALUE (MINUTES) Organism AOSept(~) Composition of the Invention Pseudomonas aeruginosa 0.54 0.53 StaphYlococcus epidermidis 3.4 1.7 Serratia marcescens 2.4 3.5 Candida albicans 10 5.7 Asper~illus fumigatus 12.3 7.1 From the results it can be seen that the modified AOSept~) formulation of the invention is particularly effective against fungal spores and staphylococcal strains.
Further tests of the inventors have revealed that the improvement of the invention is applicable to only buffered hydrogen peroxide formulation and not to unbuffered solutions.
For purposes of this test Aspergillus fumi~atus was chosen as the test organisrn. Two representative hydrogen peroxide formulations were used. AOSept(~), as previously indicated, is the commercially available 3 % stabilized hydrogen peroxide formulation that is buffered. LenSept~) is a commercially available stabilized hydrogen peroxide formulation which is not buffered. These solutions were compared for their killing efficacy as the controls. To each of these control forrnulations were added specified amounts of various surfactants and the killing efficacy of the resultant solutions was determined. The test results are presented hereinafter. In these tests the I)-value is the time necessary to kill 90 % of the active species.
First Control: The D-Value for Lensept(~ is 8.5 minutes.
The D-Value for Lensept(~ comprising 0.1 % Tetronic 1302 is 10.8 minutes.
The D-Value for Lensept(~) comprising 0.4 % Tween 8() is 9.1 minutes.
The D-Value for Lensept(~) comprising 0.4 % Tyloxapol is 7.9 minutes.
The D-Value for Lensept(~) comprising 0.4 % Pluronic F 127 is 7.6 minutes.
The D-Value for Lensept(g) comprising 0.4 % Miranol 2MCA is 8.7 minutes.
The D-Value for Lensept(~) comprising 0.4 % Varsulf 30 - 40 % is 9.4 minutes.
Second Control: The D-Value for AOSept(E~) is 12.3 minutes.
The D-Value for AOSept(~' comprising 0.1 % Tetronic 1302 is 6.6 minutes.
The D-Value for AOSept(~ comprising 0.4 % Tween 80 is 7.7 minutes.
The D-Value for AOSept(~ comprising 0.4 % Tyloxapol is 8 minutes.
The D-Value for AOSept(~) comprising 0.4 % Pluronic F 127 is 7 minutes.
The D-Value for AOSept(~) comprising 0.4 % Miranol 2MCA is 4 minutes.
The D-Value for AOSept~) comprising 0.4 % Varsulf 30 - 40 % is 6.9 minutes.
From the above data it can be seen that in the case of the addition of the surfactants to the AOSept(~) formulation, the killing efficacy was significantly increased in each case com-pared with the ef~lcacy of the AOSept(g) alone. However, with the unbuffered LenSept(~
formulation, the addition of the surfactants either had an adverse affect on the killing efficacy (the time increased) or (in two cases) had a slight affect in improving it.
In general, the hydrogen peroxide systems involve a hydrogen peroxide-containingdisinfecting solution into which the contact lenses to be disinfected are placed and allowed to remain for a required period of time. Nascent oxygen is released providing a germicidal effect. Following the requisite time period a purposeful inactivation of the hydrogen peroxide is conducted, for example, with a platinum catalyst. Following inactivation, the contact lens may be reinserted into the eye.
The hydrogen peroxide disinfecting solutions may be of the buffered or unbuffered type.
As examples, AOSept(g) is a stabilized 3 % hydrogen peroxide solution made isotonic with sodium chloride and buffered to an approximate pH 6.9 with phosphates. On the other hand, LenSept(~) is a non-buffered 3 % hydrogen peroxide formulation.
The present invention is based upon the discovery that it is possible to improve the killing effectiveness and the rate of kill of both fungi and bacteria by modifying the buffered hydrogen peroxide disinfecting solution to incorporate therein an ocularly compatible surface active agent in a specified amount. Thus, the invention provides an improvement in a buffered hydrogen peroxide disinfecting solution which comprises incorporating into said solution from about 0.1 % to about 1.0 % by weight of the solution of an ocularly compatible surface active agent. Thus, the invention is directed to, in a buffered hydrogen peroxide formulation for disinfecting contact lenses, the improvement wherein said formulation contains from about 0.1 % to about 1.0 % by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation, and to improved buffered hydrogen peroxide formulations comprising from about 0.1 % to about 1.0 % by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation, and to the use of such formulations for the disinfection of contact lenses.
Gaglia, Jr., U.S. Patent No. 3,912,451 discloses buffered hydrogen peroxide solutions of the type to which the present invention can be applied and for which improvement can be achieved.
By addition of the surface active agent to the buffered hydrogen peroxide disinfecting solution it is possible to improve the killing effectiveness and the rate of kill of both fungi and bacteria.
2~741Q8 With most 3 % hydrogen peroxide formulations, there are some viable organisms remaining even after a 30 minute soaking time of the contact lens. However, with the improvement of this invention, it is possible to provide a formulation in which there are no viable organisms after a 30 minute soaking time. With the current peroxide formulations there is a "lag" time between the time when the organisms are placed in the peroxide and the time when actual killing occurs. With the addition of the surface active agent, this "lag" time is reduced significantly and the rate of kill is enhanced.
In the literature it has been indicated that hydrogen peroxide formulations are not effective for contact lenses without a full-strength soaking for a minimum of 55 minutes. With this invention, however, it is possible to reduce considerably the disinfection time and obtain more complete disinfection.
The hydrogen peroxide formulations to which the surface active agent is added are of the buffered type. In general, in formulating such solutions a 3 % by weight hydrogen peroxide solution is formulated to contain 0.85 % by weight soldium chloride. Upon the ultimate conversion of the H22 to water and oxygen by catalyst this will yield an approximately isotonic saline solution as the final product. With the sodium chloride there is added to the H2O2 solution the necessary buffer system to buffer the 0.85 % aqueous sodium chloride solution to the desired pH of about 6.9 to 7.1.
The buffer system may comprise a suitable combination of monobasic sodium phosphate and dibasic sodium phosphate. Other satisfactory buffer systems may be employed which give substantially equivalent results in buffering to a pH of 6.9 to 7.1. As examples there can be mentioned tartrate, succinate and glycine buffers or the MacIlvaine phosphate-citrate buffer as described in J. Biol. Chem., 183 (1921).
To the solution can also be added a hydrogen peroxide stabilizer such as sodium stannate or sodium nitrate. Such stabilizers are known in the art. In addition, as the stabilizer there can be employed diethylene triamine penta (methylenephosphonic acid) or a physiologically compatible salt thereof (see U.S. Patent No. 4,889,689).
As an example of the buffered type hydrogen peroxide formulation, there can be mentioned the commercially available AOSept~) forrnulation.
2~7~1~8 In the broadest sense the surface active agents which can be used are those which are ocularly compatible and which function in the buffered hydrogen peroxide formulations to improve the killing effectiveness of such formulations. Preferably the surface active agent is a nonionic surface active agent. As specific examples of the surface active agents the following may be mentioned:
Polyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactants which are more commonly known as "Tetronic(~)" type surfactants. These are also generally known by the generic name "poloxamine" and are commercially available from BASF-Wyandotte Corp.
Polyoxyethylene-polyoxypropylene nonionic surfactants sold under the trademark "Pluronic(~)" by BASF-Wyandotte Corp. These surfactants are generally known as "poloxamers" and typically have a molecular weight of between about 2,000 and about 5,000.
Polysorbates, such as "Tween(g)" surfactants (ICI Americas) including, for example poly-sorbate 20, 40, 60, 65, 80 and 85.
Tyloxapol, such as "Superinone(~)" detergent (Winthrop).
Miranol(g) amphoteric surfactants from Miranol Inc. such as "Miranol(~)" 2MCA which is lauryl sulfate salt of an amphoteric surfactant derived from coconut imidazoline.
Varonic(~ LI surfactants such as Varonic(~ LI-63 and LI-67 which are ethoxylatedglyceryl monococoates. These are commercially available from Sherex Chemical Company, Inc..
Varsulf anionic sulfosuccinates such as Varsulf SBFA-30 and Varsulf SBL-203. These are commercially available from Sherex Chemical Company, Inc..
The foregoing are merely illustrative and not exhaustive of the surface active agents which can be employed in the invention.
One skilled in the art will be able to readily determine whether a given surface active agent or mixture of such agents can be employed. First, it is necessary to determine that 20741~8 such aKent or mixture of agents is ocularly compatible. Tests for determining such compatibility are well known in the art~. Such agent or mixture must not cause irritation or damage to the eye of a contact lens wearer. Secondly, the agent or mixture must be one which improves the killing efficacy of the buffered H2O2 formulation. Standard challenge organisms are known against which the buffered H2O2 formulation alone and that formu-lation containing the surface active agent or mixture can be compared. It is not, of course, essential that the agent or mixture of agents improve the efficacy against every challenge organism, it being most important that the overall spectrum of activity be improved.
It is also to be noted that these surface active agents can be employed alone or in combination. Preferred is e.g. a mixture of a poloxamine type and a poloxamer type surface active agent. Also preferred is a mixture of a poloxamine type and a polysorbate type surface active agent.
The surface active agent is added to the hydrogen peroxide formulation in an amount from about 0.1 % to about 1.0 % by weight of the formulation, preferably from about 0.1 % to about 0.6 % by weight of the formulation and more preferred from about 0.1 to about 0.4 % by weight of the formulation.
Particularly suitable for use in the invention are the nonionic poloxamine and poloxamer type surfactants as disclosed in European Patent Application EP-A2-439,429. These materials offer the further advantage of providing conditioning properties for the contact lenses by rendering the contact lens surface more wettable so that proteins, lipids and other tear ~llm substituents do not adhere to and form deposits on the lens surface. Some relevant parts of EP-A2-439,429 are repeated hereinafter:
"The present invention relates to a conditioning solution for contact lenses which comprises an effective amount of a polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant having a hydrophile-lipophile balance of seven or below. These surfactants preferably have a molecular weight of between about 3,600 and about 9,000. Such surfactants are typically known generally as "Poloxamine", and sold under the trademark Tetronics(~) (BASF-Wyandotte Corp.).
Preferred are those solutions wherein said polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant has a polyoxyethylene concentration between about 10 % and about 20 % by weight.
20741~8 The solution may also have an effective amount of a polyoxyethylene-polyoxy-propylene nonionic surfactant having a hydrophile-lipophile balance of seven or below and a polyo~cyethylene concentration of less than about 20 % by weight. Such surfactants are generally known as "Poloxamers" and sold under the trademark Pluronics(~) (BASF-Wyandotte Corp.). They typically have a molecular weight of between about 2,000 and about 5,000.
.....
The polyoxyethylene-polyoxypropylene substituted ethylenediamine nonionic surfactant and the polyoxyethylene-polyoxypropylene nonionic surfactant are bothsurface active agents which have as low a hydrophile-lipophile balance (HLB) as will be tolerated in the formulations. The low HLB values in the surface active agent indicate a high affinity for hydrophobic (lipophilic) surfaces. These surfaces active agents strongly adhere to those hydrophobic regions of the contact lens and render them hydrophilic. This adherence forms a "barrier" to potential absorbance, and keeps them from the surface of the lens. Furthermore, this increase in hydrophilicity simultaneously decreases the thermodynamic driving force for protein and lipid absorption, thereby retarding tear film deposits.
As mentioned hereinbefore the poloxamine type surfactants are more commonly known as Tetronic(~) type surfactants. The Tetronic(~) type surfactant is a tetrafunctional block copolymer derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine, and is represented by the followingstructure:
H-(OCH2CH2)m3~(0cHcH2)n3 \ /(CH2lHO)n1-(cH2cH2o)m1-H
~ N-CH2-CH2-N
H-(OCH2CH2)m4~(0clHcH2)n4 \(CH2CHO)n2-(CH2CH20)m2-H
wherein nl to n4 and ml to m4 are numbers being a function of the desired molecular weight and the ratio of ethyleneoxy groups to propyleneoxy groups. The 7 ~ 41~8 preparation thereof can be found in U.S. Patent No. 2,979,528, which is incorporated herein by reference. For convenience purposes, these nonionic surfactants will be identified generally as Tetronic(~, with a numeral suffix to identify a particular grade of material as available from BASF-Wyandotte Corp.
It has been surprisingly discovered that only tetronics having a hydrophile-lipophile balance of seven or below are suitable for use in the conditioning solution of the present invention. Such tetronics typically have the molecular weight of betweenabout 3,600 and about 9,000 and include Tetronic 701; 702; 901; 1101; 1102; 1301;
1302; 1501; and 1502 from BASF-Wyandotte.
The poloxamer type surfactants comprise a series of closely related block polymers that may generally be classified as polyoxyethylene-polyoxypropylene condensatesterminating in hydroxyl groups. They are formed by the condensation of propyleneoxide onto a propylene glyconucleus followed by the condensation of ethylene oxide onto both ends of polyoxypropylene base. The polyoxyethyl hydrophilic groups on the ends of the molecule are controlling length to constitute anywhere from 10 % to 80 % by weight of the final molecule. The structure of the polyethylene-polyoxy-propylene nonionic surfactant is preferably as follows:
HO-(CH2CH20)X1 -(CH2CHO)y~(CH2CH20)x2~H
wherein xl, x2 and y are numbers being a function of the desired molecular weight and the ratio of ethyleneoxy groups to propyleneoxy groups. For convenience purposes, these nonionic surfactants will be referred to herein as Pluronic(~) generally, with a numerical suffix to identify a particular grade of material asavailable from BASF-Wyandotte Corp.
It has further been discovered that the polyoxyethylene-polyoxypropylene nonionic surfactant useful in the present invention must have a HLB of seven or below and a polyoxyethylene concentration of less than about 20 % by weight. Such preferred surfactants include Pluronic L61, L81, L101 and L121 from BASF-Wyandotte Corp.
These polyoxyethylene-polyoxypropylene nonionic surfactants have a molecular weight of between about 2,000 and about 5,000."
20~41~-~
Also particularly suitable for use is a mixture of a poloxamine, e.g. poloxamine 1302 (lbtronic(~)), and a polysorbate, e.g. polysorbate 80 (Tween(~ 80), in amounts of about 0.1 % by weight and about 0.4 % by weight respectively.
In order to exemplify the invention, compositions were compared for their relative dis-infection capacity in respect to certain challenge microorganisms. The organisms tested are the FDA challenge organisms for disinfection solutions. The time required to kill 50 %
of the colony forming units (CFU) in solution was designated as the D-value. The initial solution employed was a commercially available AOSept(~) solution which is a 3 %buffered hydrogen peroxide solution also containing a hydrogen peroxide stabilizer. The solution of the present invention for comparison is prepared by adding to the commercially available AOSept~ initial solution, a mixture of polyoxamine 1302 (Tetronic~)) and polysorbate 80 (Tween(~) 80) in amounts sufficient to constitute 0.1 %
and 0.4 % by weight respectively of the formulation. The results are shown in the table below:
D-VALUE (MINUTES) Organism AOSept(~) Composition of the Invention Pseudomonas aeruginosa 0.54 0.53 StaphYlococcus epidermidis 3.4 1.7 Serratia marcescens 2.4 3.5 Candida albicans 10 5.7 Asper~illus fumigatus 12.3 7.1 From the results it can be seen that the modified AOSept~) formulation of the invention is particularly effective against fungal spores and staphylococcal strains.
Further tests of the inventors have revealed that the improvement of the invention is applicable to only buffered hydrogen peroxide formulation and not to unbuffered solutions.
For purposes of this test Aspergillus fumi~atus was chosen as the test organisrn. Two representative hydrogen peroxide formulations were used. AOSept(~), as previously indicated, is the commercially available 3 % stabilized hydrogen peroxide formulation that is buffered. LenSept~) is a commercially available stabilized hydrogen peroxide formulation which is not buffered. These solutions were compared for their killing efficacy as the controls. To each of these control forrnulations were added specified amounts of various surfactants and the killing efficacy of the resultant solutions was determined. The test results are presented hereinafter. In these tests the I)-value is the time necessary to kill 90 % of the active species.
First Control: The D-Value for Lensept(~ is 8.5 minutes.
The D-Value for Lensept(~ comprising 0.1 % Tetronic 1302 is 10.8 minutes.
The D-Value for Lensept(~) comprising 0.4 % Tween 8() is 9.1 minutes.
The D-Value for Lensept(~) comprising 0.4 % Tyloxapol is 7.9 minutes.
The D-Value for Lensept(~) comprising 0.4 % Pluronic F 127 is 7.6 minutes.
The D-Value for Lensept(g) comprising 0.4 % Miranol 2MCA is 8.7 minutes.
The D-Value for Lensept(~) comprising 0.4 % Varsulf 30 - 40 % is 9.4 minutes.
Second Control: The D-Value for AOSept(E~) is 12.3 minutes.
The D-Value for AOSept(~' comprising 0.1 % Tetronic 1302 is 6.6 minutes.
The D-Value for AOSept(~ comprising 0.4 % Tween 80 is 7.7 minutes.
The D-Value for AOSept(~ comprising 0.4 % Tyloxapol is 8 minutes.
The D-Value for AOSept(~) comprising 0.4 % Pluronic F 127 is 7 minutes.
The D-Value for AOSept(~) comprising 0.4 % Miranol 2MCA is 4 minutes.
The D-Value for AOSept~) comprising 0.4 % Varsulf 30 - 40 % is 6.9 minutes.
From the above data it can be seen that in the case of the addition of the surfactants to the AOSept(~) formulation, the killing efficacy was significantly increased in each case com-pared with the ef~lcacy of the AOSept(g) alone. However, with the unbuffered LenSept(~
formulation, the addition of the surfactants either had an adverse affect on the killing efficacy (the time increased) or (in two cases) had a slight affect in improving it.
Claims (9)
1. In a buffered hydrogen peroxide formulation for disinfecting contact lenses, the improvement wherein said formulation contains from about 0.1 % to about 1.0 % byweight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation.
2. A formulation according to claim 1 wherein the surface active agent is a nonionic surface active agent.
3. A formulation according to claim 2 wherein the surface active agent is a poloxamine.
4. A formulation according to claim 1 wherein a mixture of two surface active agents is employed.
5. A formulation according to claim 4 which employs a mixture of a poloxamine type and a poloxamer type surface active agent.
6. A formulation according to claim 4 which employs a mixture of about 0.1 % by weight of the formulation of a poloxamine and about 0.4 % by weight of the formulation of a polysorbate.
7. A method for improving the efficacy of a buffered hydrogen peroxide formulation for disinfecting contact lenses which comprises incorporating into said formulation from about 0.1 % by weight to about 1.0 % by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation.
8. A buffered hydrogen peroxide formulation comprising from about 0.1 % to about 1.0 %
by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation.
by weight of the formulation of at least one ocularly compatible surface active agent which improves the killing efficacy of said buffered hydrogen peroxide formulation.
9. The use of a formulation according to claim 8 for the disinfection of a contact lens.
FD 4.7/JD
FD 4.7/JD
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US733,115 | 1991-07-19 | ||
| US07/733,115 US5523012A (en) | 1991-07-19 | 1991-07-19 | Hydrogen peroxide disinfection solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2074108A1 true CA2074108A1 (en) | 1993-01-20 |
Family
ID=24946302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002074108A Abandoned CA2074108A1 (en) | 1991-07-19 | 1992-07-17 | Hydrogen peroxide disinfection solutions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5523012A (en) |
| EP (1) | EP0524150B1 (en) |
| JP (1) | JP3808512B2 (en) |
| AT (1) | ATE186648T1 (en) |
| AU (1) | AU657773B2 (en) |
| CA (1) | CA2074108A1 (en) |
| DE (1) | DE69230304T2 (en) |
| FI (1) | FI923281A (en) |
| IE (1) | IE922337A1 (en) |
| IL (1) | IL102481A0 (en) |
| NO (1) | NO302275B1 (en) |
| NZ (1) | NZ243606A (en) |
| ZA (1) | ZA925355B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI93609C (en) * | 1993-09-24 | 1995-05-10 | Finnsusp Ab Oy | Use of a biodegradable detergent in contact lens care solutions, a treatment solution and a method for treating contact lenses |
| FR2718924B1 (en) * | 1994-04-22 | 1996-06-07 | Soyez Jean Louis | Application of hydrogen peroxide for the preventive and curative treatment of leaf and air diseases of plants. |
| US6346279B1 (en) * | 1998-12-14 | 2002-02-12 | Virox Technologies, Inc. | Hydrogen peroxide disinfectant with increased activity |
| MY128134A (en) | 2000-09-28 | 2007-01-31 | Novartis Ag | Compositions and methods for cleaning contact lenses |
| AU2595002A (en) * | 2000-11-08 | 2002-05-21 | Bio Concept Lab | L-histidine in ophthalmic solutions |
| TW200300448A (en) * | 2001-11-21 | 2003-06-01 | Novartis Ag | Conditioning solution for contact lenses |
| CA2756052C (en) * | 2002-02-12 | 2014-04-08 | Virox Technologies Inc. | Enhanced activity hydrogen peroxide disinfectant |
| GB0219345D0 (en) * | 2002-08-20 | 2002-09-25 | Givaudan Sa | Improvements in or relating to organic compounds |
| WO2004045281A2 (en) * | 2002-11-15 | 2004-06-03 | Virox Technologies Inc. | Hydrogen peroxide disinfectant containing an acid and/or an alcohol |
| US20080305182A1 (en) * | 2002-11-15 | 2008-12-11 | Ramirez Jose A | Hydrogen peroxide disinfectant containing a cyclic carboxylic acid and/or aromatic alcohol |
| US20050118132A1 (en) * | 2003-12-01 | 2005-06-02 | Erning Xia | Nonionic surfactant containing compositions for cleaning contact lenses |
| US7029704B2 (en) * | 2003-12-29 | 2006-04-18 | Woods Jr Clifford E | Anti-itch solution |
| US20060073973A1 (en) * | 2004-10-05 | 2006-04-06 | Mcfadden David T | Composition, process and method of use for treating algae and pests |
| US20090239954A1 (en) * | 2008-03-19 | 2009-09-24 | Collins Gary L | Phosphate buffered ophthalmic solutions displaying improved efficacy |
| US20090304608A1 (en) * | 2008-06-05 | 2009-12-10 | Innovasource, Llc | Aqueous Hydrogen Peroxide Solution for Use as a Disinfectant or Anti-Microbial Personal Care Product |
| US7951404B2 (en) | 2008-07-11 | 2011-05-31 | Sanosil Ag | Concentrate for preparing a disinfectant and methods for its preparation and use |
| CA2733644C (en) * | 2008-09-30 | 2013-12-03 | Virox Technologies Inc. | Concentrated hydrogen peroxide disinfecting solutions |
| CA2775969C (en) * | 2009-11-17 | 2016-12-20 | Novartis Ag | A hydrogen peroxide solution and kit for disinfecting contact lenses |
| EP2544725A1 (en) * | 2010-03-08 | 2013-01-16 | Novartis AG | Active oxygen disinfection system and use thereof |
| US8999312B2 (en) | 2010-06-02 | 2015-04-07 | Alcon Research, Ltd. | Use of PBO-PEO-PBO block copolymers in ophthalmic compositions |
| US8932646B2 (en) * | 2010-06-18 | 2015-01-13 | Bausch & Lomb Incorporated | Peroxide contact lens care solution |
| US9011932B2 (en) | 2010-09-16 | 2015-04-21 | Bausch & Lomb Incorporated | Contact lens care system with peroxide |
| CA2920286C (en) * | 2013-09-27 | 2019-02-12 | Novartis Ag | Compositions and methods for disinfecting and cleaning contact lenses |
| US10525158B2 (en) | 2014-04-03 | 2020-01-07 | Novartis Ag | Electrochemical system for disinfecting and cleaning contact lenses |
| CA2939717C (en) | 2014-04-03 | 2019-02-26 | Novartis Ag | System for disinfecting contact lenses |
| CA2961639A1 (en) | 2014-09-17 | 2016-03-24 | Lonza, Inc. | Activated disinfectant hydrogen peroxide compositions |
| US10450535B2 (en) | 2017-10-18 | 2019-10-22 | Virox Technologies Inc. | Shelf-stable hydrogen peroxide antimicrobial compositions |
| CN113286515A (en) | 2018-11-12 | 2021-08-20 | 戴弗西公司 | Antimicrobial compositions containing C3-C6N-alkyl-gamma-butyrolactams and peroxygen |
| US11717591B2 (en) | 2018-11-29 | 2023-08-08 | Better Vision Solutions LLC | Methods for disinfecting contact lenses with a manganese-coated disc, and related contact lens treatment systems |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USB724600I5 (en) * | 1968-04-26 | |||
| US3912451A (en) * | 1973-06-04 | 1975-10-14 | Warner Lambert Co | Method for removing hydrogen peroxide from soft contact lenses |
| US4046706A (en) * | 1976-04-06 | 1977-09-06 | Flow Pharmaceuticals, Inc. | Contact lens cleaning composition |
| US4323467A (en) * | 1980-11-24 | 1982-04-06 | Syntex (U.S.A.) Inc. | Contact lens cleaning, storing and wetting solutions |
| JPS57186733A (en) * | 1981-05-13 | 1982-11-17 | Toyo Contact Lens Co Ltd | Agent for use in contact lenses |
| US4414127A (en) * | 1981-07-06 | 1983-11-08 | Syntex (U.S.A.) Inc. | Contact lens cleaning solutions |
| DE3277567D1 (en) * | 1981-12-21 | 1987-12-10 | Titmus Eurocon Kontaktlinsen | Method for disinfecting and cleaning contact lenses |
| US4820352A (en) * | 1983-01-10 | 1989-04-11 | Bausch & Lomb Incorporated | Cleaning and conditioning solutions for contact lenses and methods of use |
| FR2578332B1 (en) * | 1985-01-30 | 1989-03-31 | Air Liquide | ASEPTISAN COMPOSITION FOR CONTACT LENSES |
| GB8507678D0 (en) * | 1985-03-25 | 1985-05-01 | Univ Bath | Cleaning/disinfection of contact lenses |
| US4880601A (en) * | 1985-09-27 | 1989-11-14 | Laboratoires, P.O.S. | Hydrogen peroxide disinfecting system for contact lenses |
| DE3626082A1 (en) * | 1986-07-31 | 1988-02-11 | Henkel Kgaa | DISINFECTANT AND CLEANER SYSTEM FOR CONTACT LENSES |
| US4889689A (en) * | 1986-10-14 | 1989-12-26 | Ciba-Geigy Corporation | Method of disinfecting a soft contact lens with a diethylene triamine penta(methylenephosphonic acid) stabilized hydrogen peroxide solution |
| DE3701129A1 (en) * | 1987-01-16 | 1988-07-28 | Henkel Kgaa | METHOD FOR PRODUCING DISINFECTING CONTACT LENS CLEANING AGENT TABLETS |
| US4812173A (en) * | 1987-05-01 | 1989-03-14 | Ciba-Geigy Corporation | Stabilized hydrogen peroxide contact lens disinfecting solution |
| US5017238A (en) * | 1989-08-30 | 1991-05-21 | Dow Corning Corporation | Aqueous cleaning dispersions using adsorptive polymeric powder and method of using |
| IL97081A0 (en) * | 1990-02-09 | 1992-03-29 | Abbott Lab | Electrolytic cleaning and disinfecting solution |
| US5145644A (en) * | 1990-12-20 | 1992-09-08 | Allergan, Inc. | Hydrogen peroxide destroying compositions and methods of making and using same |
-
1991
- 1991-07-19 US US07/733,115 patent/US5523012A/en not_active Expired - Lifetime
-
1992
- 1992-07-10 AT AT92810529T patent/ATE186648T1/en not_active IP Right Cessation
- 1992-07-10 EP EP92810529A patent/EP0524150B1/en not_active Expired - Lifetime
- 1992-07-10 DE DE69230304T patent/DE69230304T2/en not_active Expired - Lifetime
- 1992-07-13 IL IL102481A patent/IL102481A0/en unknown
- 1992-07-16 NO NO922823A patent/NO302275B1/en unknown
- 1992-07-16 AU AU20347/92A patent/AU657773B2/en not_active Ceased
- 1992-07-17 CA CA002074108A patent/CA2074108A1/en not_active Abandoned
- 1992-07-17 ZA ZA925355A patent/ZA925355B/en unknown
- 1992-07-17 NZ NZ243606A patent/NZ243606A/en unknown
- 1992-07-17 FI FI923281A patent/FI923281A/en not_active Application Discontinuation
- 1992-07-17 JP JP21231092A patent/JP3808512B2/en not_active Expired - Lifetime
- 1992-07-17 IE IE233792A patent/IE922337A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI923281A (en) | 1993-01-20 |
| JPH05201816A (en) | 1993-08-10 |
| AU2034792A (en) | 1993-01-21 |
| NZ243606A (en) | 1995-04-27 |
| AU657773B2 (en) | 1995-03-23 |
| EP0524150B1 (en) | 1999-11-17 |
| NO302275B1 (en) | 1998-02-16 |
| NO922823D0 (en) | 1992-07-16 |
| JP3808512B2 (en) | 2006-08-16 |
| ZA925355B (en) | 1993-02-24 |
| IE922337A1 (en) | 1993-01-27 |
| US5523012A (en) | 1996-06-04 |
| NO922823L (en) | 1993-01-20 |
| EP0524150A1 (en) | 1993-01-20 |
| ATE186648T1 (en) | 1999-12-15 |
| DE69230304D1 (en) | 1999-12-23 |
| DE69230304T2 (en) | 2000-12-21 |
| FI923281A0 (en) | 1992-07-17 |
| IL102481A0 (en) | 1993-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0524150B1 (en) | Improvement in hydrogen peroxide disinfection solutions | |
| US5424078A (en) | Aqueous ophthalmic formulations and methods for preserving same | |
| EP0180309B1 (en) | Improved disinfecting and preserving solutions for contact lenses and methods of use | |
| US4529535A (en) | Soft contact lens wetting solution containing preservative system and method | |
| CA2430127C (en) | Aqueous disinfecting system comprising a microbicide and 1,3-bis(tris[hydroxymethyl]methylamino)propane | |
| JP2000513001A (en) | Use of low molecular weight amino alcohols in ophthalmic compositions | |
| EP0564510A1 (en) | Method and composition for disinfecting contact lenses | |
| KR20010031990A (en) | Treatment of contact lenses with aqueous solution comprising an alkali carbonate | |
| EP1416975B1 (en) | Disinfecting and cleansing system for contact lenses | |
| EP0674532B1 (en) | Contact lens disinfecting solution containing an oxidizing agent and polyvinyl pyrrolidone | |
| US7282178B2 (en) | Composition and method for cleaning lipid deposits on contact lenses | |
| KR20030040395A (en) | Compositions and methods for cleaning contact lenses | |
| JP2005502392A (en) | Composition containing vitamin surfactant and method of using the same | |
| Cano-Parra et al. | Antibacterial and antifungal effects of soft contact lens disinfection solutions | |
| US6514528B1 (en) | Composition and method for inhibiting uptake of biguanide disinfectants by poly(ethylene) | |
| AU627195B2 (en) | Antimicrobial ophthalmic solutions containing dodecyl- dimethyl-(2-phenoxyethyl)-ammonium bromide and methods of using the same | |
| US20060276359A1 (en) | Composition and method for cleaning lipid deposits on contact lenses | |
| IE910338A1 (en) | Electrolytic cleaning and disinfecting solution | |
| CA2545962A1 (en) | Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions | |
| EP0175490A2 (en) | Contact lens treatment compositions and their uses | |
| IE920220A1 (en) | Method and composition for disinfecting contact lenses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |